Heart regeneration therapy by autologous Adipose Tissue Derived Stromal Cells
- Conditions
- Heart failure that occurred by prior ischemic event whose ejection fraction is less than 40%
- Registration Number
- JPRN-jRCTb040190115
- Lead Sponsor
- Kaneko Shuichi
- Brief Summary
Regarding the primary endpoint's safety, no adverse events were observed during the perioperative period and 6 months in all 3 patients. As secondary endpoints, the changes in cardiopulmonary function were evaluated. In one patient (case 2), maximal oxygen uptake increased, and in two patients (cases 2 and 3), exercise tolerance (6 minutes walking distance) improved. On the other hand, there was one patient (case 1) in which the cardiopulmonary function did not change.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 3
Heart failure that occurred by prior ischemic event whose ejection fraction is less than 40%
1.Complicated severe other organ disease.
2.Patients with malignancy.
3.History of chemotherapy or irradiation within 4 weeks.
4.Patients with immunodeficiency
5.Pregnancy or possibility of pregnancy
6.Candidates who are judged to be not applicable to this study by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method